登录

制药公司Avenacy在美国市场推出呋塞米注射液

Avenacy Announces Launch of Furosemide for Injection in the U.S. Market

businesswire 等信源发布 2024-03-20 18:00

可切换为仅中文


SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Furosemide for Injection in the United States as a therapeutic equivalent generic for Lasix® for Injection (furosemide) approved by the U.S.

伊利诺伊州绍姆堡(商业新闻短讯)--专注于提供关键注射药物的专业制药公司Avenacy今天宣布,它已在美国推出注射用呋塞米,作为美国批准的Lasix®注射用(呋塞米)的治疗等效仿制药。

Food and Drug Administration. Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired..

食品和药物管理局。速尿适用于成人和儿科患者,用于治疗与充血性心力衰竭,肝硬化和肾脏疾病(包括肾病综合征)相关的水肿。当需要具有更大利尿潜力的药物时,速尿特别有用。

“The launch of Furosemide for Injection builds on the two launches announced earlier this week and further demonstrates the speed at which we are progressing the business,” said Jeff Yordon, Co-Founder and CEO of Avenacy. “The reception by potential partners and investors to Avenacy at DCAT has been outstanding and, with five products now launched since our formation in October, we look forward to continuing to execute against our goal of launching more than 20 products this year.”.

Avenacy联合创始人兼首席执行官杰夫·约登(Jeff Yordon)表示:“注射用呋塞米的推出建立在本周早些时候宣布的两次推出的基础上,进一步证明了我们业务发展的速度。DCAT的潜在合作伙伴和投资者对Avenacy的接待非常好,自10月份成立以来,我们已经推出了五款产品,我们期待着继续实现今年推出20多种产品的目标。”

Avenacy's Furosemide will come in packs of 25 units of 100 mg/10 mL doses. In line with Avenacy’s mission to champion patient safety and streamline patient care, Furosemide for Injection will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection.

Avenacy的速尿将以25个单位的100毫克/10毫升剂量包装。根据Avenacy维护患者安全和简化患者护理的使命,注射用呋塞米将采用该公司高度分化的包装和标签,以支持准确的药物选择。

Avenacy will begin shipping Furosemide for Injection to wholesale partners next week. The Company is supported by a global network of development and FDA-approved cGMP-certified contract manufacturing partners..

Avenacy将于下周开始向批发合作伙伴运送注射用速尿。该公司得到了全球开发网络和FDA批准的cGMP认证合同制造合作伙伴的支持。

Furosemide for Injection had U.S. sales of approximately $33 million for the twelve months ending in June 2023.

截至2023年6月的12个月内,注射用速尿在美国的销售额约为3300万美元。

To learn more about Avenacy’s products or the Company’s exciting growth plans for 2024, please see the Avenacy management team at DCAT Week 2024 taking place in New York City from March 18-21st. To request a meeting with a member of the Avenacy team, please reach out to Avenacy@fticonsulting.com.

要了解更多关于Avenacy的产品或公司2024年令人兴奋的增长计划,请参阅3月18日至21日在纽约举行的2024年DCAT周的Avenacy管理团队。要请求与Avenacy团队的成员会面,请联系Avenacy@fticonsulting.com.

Furosemide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required and dose and dose schedule must be adjusted to the individual patient's needs.

速尿是一种有效的利尿剂,如果服用过量,会导致严重的利尿,并导致水和电解质的消耗。因此,需要仔细的医疗监督,剂量和剂量时间表必须根据患者的需求进行调整。

Furosemide is indicated as adjunctive therapy in acute pulmonary edema. The intravenous administration of furosemide is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema. If gastrointestinal absorption is impaired or oral medication is not practical for any reason, furosemide is indicated by the intravenous or intramuscular route.

速尿被认为是急性肺水肿的辅助治疗。当需要快速利尿时,例如在急性肺水肿中,指示静脉内施用速尿。如果胃肠道吸收受损或由于任何原因口服药物不可行,呋塞米可通过静脉或肌肉注射途径指示。

Parenteral use should be replaced with oral furosemide as soon as practical..

肠胃外使用应尽快用口服速尿代替。

Lasix® is a registered trademark of Sanofi S.A.

Lasix®是赛诺菲公司的注册商标。

About Avenacy

关于Avenacy

Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain.

Avenacy是一家总部位于美国的专业制药公司,专注于提供关键的注射药物,用于在各种医疗监督环境中治疗患者,从急诊医院到门诊诊所和医生办公室。通过严格和优化的选择过程,该公司正在建立一条高质量的FDA批准的注射产品管道,以确保有弹性的组合能够满足当今动态药物供应链的需求。

With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications..

凭借经验丰富的团队、对质量和可靠性的承诺以及旨在促进安全高效的患者护理的产品,Avenacy努力成为基本药物领域值得信赖的合作伙伴。